Chargement en cours...
Unanticipated Increases in Hepatic Steatosis among HIV Patients Receiving MR Antagonist Eplerenone for NAFLD
BACKGROUND & AIMS: Nonalcoholic fatty liver disease is common in HIV, but there are no approved therapies. The aim of this open-label proof-of-concept study was to determine the effect of the mineralocorticoid receptor antagonist eplerenone on hepatic fat in HIV-infected patients with hepatic fa...
Enregistré dans:
| Publié dans: | Liver Int |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7939026/ https://ncbi.nlm.nih.gov/pubmed/29509992 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.13734 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|